To Give or Not to Give Anti–Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies to Patients With KRAS G13D Mutation in Advanced Colorectal Cancer

Monoclonal Antibodies ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

A novel therapeutic strategy of personalized medicine based on anti-epidermal growth factor receptor monoclonal antibodies in patients with metastatic colorectal cancer

International Journal of Oncology ◽

10.3892/ijo.2018.4322 ◽

2018 ◽

Cited By ~ 3

Author(s):

Nobuhisa Matsuhashi ◽

Takao Takahashi ◽

Satoshi Matsui ◽

Toshiyuki Tanahashi ◽

Hisashi Imai ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Growth Factor ◽

Personalized Medicine ◽

Epidermal Growth Factor ◽

Therapeutic Strategy ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Novel Therapeutic

Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

Targeted Oncology ◽

10.1007/s11523-010-0138-5 ◽

2010 ◽

Vol 5 (1) ◽

pp. 19-28 ◽

Cited By ~ 23

Author(s):

Andrea Sartore-Bianchi ◽

Katia Bencardino ◽

Federica Di Nicolantonio ◽

Federico Pozzi ◽

Chiara Funaioli ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Growth Factor Receptor ◽

Molecular Dissection ◽

Oncogenic Pathway ◽

Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer

Targeted Oncology ◽

10.1007/s11523-010-0142-9 ◽

2010 ◽

Vol 7 (4) ◽

pp. 267-267

Author(s):

Andrea Sartore-Bianchi ◽

Katia Bencardino ◽

Federica Di Nicolantonio ◽

Federico Pozzi ◽

Chiara Funaioli ◽

...

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Growth Factor Receptor ◽

Molecular Dissection ◽

Oncogenic Pathway ◽

Clinical Use of Anti–Epidermal Growth Factor Receptor Monoclonal Antibodies in Metastatic Colorectal Cancer

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ◽

10.1592/phco.28.11-supp.31s ◽

2008 ◽

Vol 28 (11 Part 2) ◽

pp. 31S-41S ◽

Cited By ~ 21

Author(s):

Dina K Patel

Keyword(s):

Colorectal Cancer ◽

Monoclonal Antibodies ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Metastatic Colorectal Cancer ◽

Growth Factor Receptor ◽

Clinical Use ◽

Epidermal growth factor receptor (EGFR) copy number (CN) as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC)

Annals of Oncology ◽

10.1093/annonc/mdx393.071 ◽

2017 ◽

Vol 28 ◽

pp. v185 ◽

Cited By ~ 3

Author(s):

J. Seligmann ◽

H. Wood ◽

S. Richman ◽

F. Elliott ◽

M. Taylor ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Copy Number ◽

Growth Factor Receptor ◽

Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.3579 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3579-3579 ◽

Cited By ~ 11

Author(s):

S. Tejpar ◽

E. Van Cutsem ◽

E. Gamelin ◽

D. Machover ◽

P. Soulie ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Irreversible Inhibitor ◽

Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3579 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3579-3579 ◽

Cited By ~ 1

Author(s):

S. Tejpar ◽

E. Van Cutsem ◽

E. Gamelin ◽

D. Machover ◽

P. Soulie ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Phase 1 ◽

Growth Factor Receptor ◽

Irreversible Inhibitor ◽

First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3659 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3659-3659 ◽

Cited By ~ 7

Author(s):

M. G. Zampino ◽

K. Lorizzo ◽

C. Massacesi ◽

A. Rizzi ◽

S. Crispino ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽

First Line ◽

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (‘Iressa’), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in advanced colorectal cancer (ACRC)

European Journal of Cancer ◽

10.1016/s0959-8049(01)80551-7 ◽

2001 ◽

Vol 37 ◽

pp. S18-S19 ◽

Cited By ~ 6

Author(s):

L. Hammond ◽

J. Figueroa ◽

L. Schwartzberg ◽

L. Ochoa ◽

M. Hidalgo ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Epidermal Growth ◽

Egfr Tki

Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib?

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-008-0722-x ◽

2008 ◽

Vol 63 (1) ◽

pp. 139-148 ◽

Cited By ~ 9

Author(s):

M. G. Zampino ◽

E. Magni ◽

L. Santoro ◽

L. Zorzino ◽

P. Dell’Orto ◽

...

Keyword(s):

Colorectal Cancer ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Growth Factor Receptor ◽